WHO Consolidated Guidelines on Tuberculosis, Module 4: Drug-Resistant Tuberculosis Treatment

WHO Consolidated Guidelines on Tuberculosis, Module 4: Drug-Resistant Tuberculosis Treatment

2020/06/15


WHO Guidelines Cover

Professor Amrita Daftary, Member of Faculty at the Dahdaleh Institute, contributed to the World Health Organization's Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment.

In 2019, new evidence pointed to the safety and efficacy of new all-oral, shorter treatment regimens for drug resistant tuberculosis (DRTB), tuberculosis (TB) that is resistant to the most common anti-TB drugs available. It had been over 50 years since the last new TB drug was developed. The guidelines are the result of a commissioned review of all evidence around the shorter, all-oral regimens.



Related Content


Next/Previous
»
«